Amplify Weight Loss Drug & Treatment ETF (THNR)
After hours:
- GlobeNewswire
Amplify ETFs Earns Four Nominations for With Intelligence Mutual Fund and ETF Awards
Innovative ETF provider recognized for their industry leadership and creativityCHICAGO, June 05, 2024 (GLOBE NEWSWIRE) -- Amplify ETFs, a leading provider of innovative exchange-traded funds, is proud to announce its nominations in four categories at this year's With Intelligence Mutual Fund and ETF Awards. Amplify funds are being recognized in the following categories: ETF Innovation of the Year: Amplify Samsung SOFR ETF (SOF) - the first ETF aimed to deliver the closely-watched Secured Overnig
- GlobeNewswire
Amplify ETFs Launches The Amplify Weight Loss Drug & Treatment ETF (THNR)
THNR invests in companies at the forefront of GLP-1 innovationCHICAGO, May 21, 2024 (GLOBE NEWSWIRE) -- Amplify ETFs announces the launch of the Amplify Weight Loss Drug & Treatment ETF (NYSE: THNR), an index-based ETF offering access to companies at the forefront of developing and marketing GLP-1 treatments. Over one billion individuals across the globe are now clinically obese, drawing significant attention to the obesity epidemic as a critical public health issue.1 With the rising global focu
